Semax brings focus, cognition, migraine, and neurological research into the July 24 PCAC meeting, with free-base and acetate votes scheduled.
Semax completes the July 2026 PCAC peptide slate—and brings the cognition and neurological side of peptide interest to center stage.
The committee will vote separately on Semax free base and Semax acetate for the Section 503A Bulks List.
Why Semax stands out on Day 2
DSIP and Epitalon bring strong sleep interest to Friday's meeting. Semax changes the subject to the brain.
Its following centers on focus, cognition, and neurological performance, giving PCAC Day 2 a distinct closing chapter.
What FDA reviewed for Semax
FDA's July 24 agenda names three reviewed uses for Semax-related bulk drug substances:
- Cerebral ischemia
- Migraine
- Trigeminal neuralgia
Those subjects make Semax one of the most neurologically focused peptides in the full two-day PCAC meeting.
The two Semax PCAC questions
PCAC will vote on Semax free base and Semax acetate separately. Favorable recommendations would move both forms forward in the 503A Bulks List process.
Watch the Semax PCAC vote
The July 24 meeting begins at 8 a.m. Eastern. Watch the official FDA PCAC live stream and follow Semax on Rebody's live vote tracker.
See the three peptides to watch at PCAC Day 2.
Semax PCAC FAQ
When is the Semax PCAC vote?
Semax is scheduled for the July 24 PCAC meeting.
Which Semax forms are being reviewed?
PCAC will vote separately on Semax free base and Semax acetate.
What uses did FDA review for Semax?
FDA reviewed cerebral ischemia, migraine, and trigeminal neuralgia.